10-QPeriod: Q1 FY2024

DEXCOM INC Quarterly Report for Q1 Ended Mar 31, 2024

Filed April 25, 2024For Securities:DXCM

Summary

DexCom, Inc. reported strong financial performance for the first quarter of 2024, with revenue increasing by 24% year-over-year to $921.0 million. This growth was primarily driven by an increase in sales volume of their continuous glucose monitoring (CGM) systems, adding approximately 600,000 users to their global customer base in the prior year. The company also demonstrated significant profitability improvements, with operating income soaring by 114% and net income more than tripling to $146.4 million, resulting in a diluted EPS of $0.36. Operationally, DexCom continues to invest in research and development to enhance its product offerings and expand into new markets, including individuals with Type 2 diabetes not using insulin. The company's balance sheet remains robust, with cash, cash equivalents, and marketable securities totaling $2.90 billion at the end of the quarter, and positive operating cash flow of $209.2 million underscores its financial strength. However, investors should note ongoing patent litigation with Abbott, which, while currently assessed as not likely to result in a material adverse outcome, remains a point of ongoing legal scrutiny.

Financial Highlights

50 data points
Beta

Revenue

$921.00M

61.0% Gross Margin

Net Income

$146.40M

15.9% Net Margin

EPS (Diluted)

$0.36

Total Assets

$6.48B

Cash & Equivalents

$851.20M

Free Cash Flow

$152.30M

Financial Statements
Beta
Revenue$921.00M
Cost of Revenue$359.10M
Gross Profit$561.90M
R&D Expenses$141.50M
SG&A Expenses$319.30M
Operating Expenses$460.80M
Operating Income$101.10M
Interest Expense$3.70M
Net Income$146.40M
EPS (Basic)$0.38
EPS (Diluted)$0.36
Shares Outstanding (Basic)390.20M
Shares Outstanding (Diluted)416.70M

Key Highlights

  • 1Revenue grew 24% year-over-year to $921.0 million, driven by increased sales volume and user base expansion.
  • 2Net income significantly increased by 201% to $146.4 million, demonstrating strong profitability.
  • 3Diluted Earnings Per Share (EPS) rose to $0.36, a substantial increase from $0.12 in the prior year period.
  • 4Operating income surged by 114% to $101.1 million, indicating improved operational efficiency.
  • 5The company generated robust operating cash flow of $209.2 million, up 35% year-over-year.
  • 6Dexcom received FDA marketing clearance for its Stelo sensor, designed for individuals with Type 2 diabetes who do not use insulin, opening a new market segment.
  • 7The company ended the quarter with a strong liquidity position, holding $2.90 billion in cash, cash equivalents, and short-term marketable securities.

Frequently Asked Questions

The primary driver of Dexcom's revenue growth in the first quarter of 2024 was the increased sales volume of their disposable continuous glucose monitoring (CGM) sensors, attributed to the continued expansion of their worldwide customer base. The company added approximately 600,000 users in the preceding year.

Dexcom experienced significant improvements in profitability. Net income more than tripled, increasing by 201% to $146.4 million, while operating income saw a substantial jump of 114% to $101.1 million. This was also reflected in the diluted EPS, which grew to $0.36 from $0.12 in the prior year quarter.

Dexcom and Abbott are involved in ongoing patent infringement litigation. In a recent trial regarding Dexcom's G6 system, a jury found infringement on one patent, but also found non-infringement on two others and invalidated a third. The jury did not award damages for the one patent found to be infringed, and Dexcom plans to challenge this finding. The company believes it is not probable that they will have an unfavorable outcome leading to a material loss, and has not recorded an accrual for a contingent liability at this time, but notes ongoing uncertainty in various international jurisdictions.

Dexcom received FDA marketing clearance for its new Stelo sensor in March 2024. This 15-day sensor is specifically designed for people with Type 2 diabetes who do not use insulin and is notable for being the first glucose biosensor that does not require a prescription. This marks an expansion into a new customer segment for the company.